Daily Brief United States: Astera Labs , International Money Express In, Advanced Micro Devices, Toro Corp, IEH Corp, Meta, NewHydrogen, Nscale, ADARx Pharmaceuticals and more

• The SP 500 index tracks the 500 largest (mostly profitable) US-listed names and is one of the most highly-tracked indices in the world.
• A spin-off completes next week, and the new company’s entry into the SP 500 is expected to trigger an intra-review deletion.
• We expect two ADDs and two DELs at the December 2026 rebalance, and two M&A deals could trigger intra-review ADDs before that.

• Western Union is acquiring International Money Express for $16/share in cash, with almost all merger conditions satisfied.
• California’s regulatory review suspension has widened the merger arbitrage spread from 12% to 50% over ten days.
• Western Union accepted New York’s concessions, indicating commitment to the merger despite IMXI’s weakened financial performance.

• Accelerating Data Center and AI Inflection: Advanced Micro Devices (AMD) has established itself as the preeminent alternative in accelerated computing and high-performance x86 architectures, raising its 2030 Server CPU Total Addressable Market (TAM) forecast from $60B to $220B while targeting ambitious growth (>60% CAGR in Data Center and >80% CAGR in AI Data Center revenues).
• Robust Structural Margin and Cash Flow Expansion: LTM revenue reached $41.3B with Q2 2026 gross margins sustaining above 51.3% and net income reaching $2,297M, driven by favorable product mix shifts toward high-margin EPYC server CPUs, Instinct AI accelerators, and holistic full rack-scale Helios system solutions.
• Valuation and Macro Risk Premium: At a last price of $629.26 with an elevated beta of 2.49, current valuation multiples price in aggressive hyperscaler capex continuation and flawless multi-generation execution against formidable competitors, demanding disciplined milestone tracking on software stack maturation (ROCm/Optima) and enterprise token cost-efficiency.

This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

• Toro is spinning off its two LPG carriers into AI OKTO (AIOK) through a 1-for-8 share distribution. AIOK will start debt free with two vessels and $45 million of cash.
• Cash and vessel values make up most of AIOK’s value, so we focus on its estimated $78.6 million NAV rather than EBITDA multiples.
• Toro’s existing NAV discount could simply carry over to both companies, especially given their small size, related-party management and concentrated voting control.

• What you need to know: • IEHC announced that it has signed $3.6M in orders for mobile defibrillator applications.
• This gives us increased confidence that IEHC’s hyperboloid connectors have strong applications in the healthcare industry.
• • The other/medical segment represented only 3.8% of sales in FY26 or ~$1.1M, and as such, is growing off a small base.

• Meta’s 20× came from underestimated duration, not a cheap entry: net income rose 76-fold while the IPO’s roughly 104× earnings multiple shrank to 25×.
• The signals were visible early: proven margins, an engaged but under-monetized audience, a feared platform shift, free user-made inventory and a founder willing to cannibalize.
• Zynga and Groupon listed in the same months with big audiences but lacked owned distribution, repeat economics or cheap inventory; Meta’s soaring capex now fails one test.

• Thermodynamic Superiority vs. Commercial Captivity: Thermochemical water splitting, such as NewHydrogen’s ThermoLoop®, bypasses the costly electricity-to-heat-to-electricity loop of conventional electrolysis, presenting a theoretical shortcut to sub-$2.00 per kilogram clean hydrogen. However, its economic viability is completely captive to the commercial scale-up of high-temperature small modular reactors (SMRs) which remain in early testing and are years away from industrial deployment.
• Capital Disconnect & Going-Concern Risks: There is a severe mismatch between NewHydrogen’s capital resources—evidenced by a net loss of $2.85 million and a cash balance of $1.44 million at the end of 2025, alongside a highly dilutive $3 million GHS Investments equity facility—and the estimated $15 million to $20 million minimum required to develop and operate an automated engineering test unit and subsequent pilot plant.
• Key-Person and Management Deficiencies: While the technical core of the company is anchored by CTO Dr. Eric McFarland and his laboratory at UC Santa Barbara, the operational leadership is led by a CEO with a background in biopharmaceutical sales. This creates significant execution risks as the company attempts to transition from academic laboratory validation into complex, high-temperature chemical engineering.

• The Execution-Funding Gap: Nscale’s headline $103.4 billion total contract value (TCV) is highly misleading; only $2.6 billion is active and generating revenue, representing approximately 25,000 active GPUs. The remaining $100.8 billion is an unbuilt backlog of 436,000 GPUs that requires billions in capital expenditure to realize, exposing the business to extreme execution and liquidity risks.
• Contract Contingencies and Concentration: Landmark agreements like the $44.6 billion Anthropic contract and $43.8 billion Microsoft contract together represent approximately 85% of Nscale’s total contract value. However, these are not fully committed cash flows; they are contingent on Nscale successfully delivering physical data center space and procuring chips, with Anthropic’s financing not yet committed.
• High Stock Dilution and Artificial Cash Flows: While Nscale’s 1H2026 revenue grew to $140.6 million, its $1.02 billion GAAP net loss (a -726% margin) was heavily driven by $113.8 million in stock-based compensation—equivalent to 81% of revenue—and $457.1 million in non-cash warrant markups. The positive $1.7 billion in operating cash flow is an accounting artifact driven by $6.5 billion in deferred customer prepayments, which GAAP treats as interest-bearing customer loans.

• ADARx upsized its IPO to 26.3 million shares at $17.00, the high end of the range, opening at $22.10 for a 30% gain.
• The offering was 10 times oversubscribed, with the top 25 accounts receiving 95% of shares and nearly 100 accounts receiving zero allocation.
• Shares closed at $19.35 after reaching $23.21, highlighting persistent selling pressure despite strong demand and a constructive biotech IPO outcome.

• Boxlight Corporation (NASDAQ: BOXL) is executing a strategic pivot from commoditized hardware distribution toward an integrated EdTech and campus safety ecosystem, combining Clevertouch interactive flat panels, FrontRow networked classroom audio/communication platforms, and Mimio/EOS software and professional services.
• Following severe top-line contraction from $176.7M in FY2023 to $109.2M in FY2025 caused by the expiration of US federal ESSER stimulus funding, financial performance showed initial operational stabilization in Q2 2026, marked by gross margin expansion to 39.88% and a return to positive quarterly net income ($0.51M).
• Substantial balance sheet leverage ($34M+ in funded debt), ongoing inventory financing obligations, and tight working capital liquidity represent the primary constraints on valuation, requiring sustained positive operating cash flow generation to ensure long-term balance sheet de-risking and equity rerating.

This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.